Back to top
Top
U.S. flag

An official website of the United States government

Dot gov

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Https

Secure .gov websites use HTTPS
A lock ( ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

Screening for Abnormal Glucose Metabolism in Patients at Risk of Developing Diabetes

Measure Information

Compare Versions of: "Screening for Abnormal Glucose Metabolism in Patients at Risk of Developing Diabetes"

The Compare function compares two years of the measure specifications found in the header of the measure's HTML. It does not include a comparison of any information in the body of the HTML, e.g., population criteria, Clinical Quality Language, or value sets.

Strikethrough text highlighted in red indicates information changed from the previous version. Text highlighted in green indicates information updated in the new eCQM version.

Compare version to

Table Options
Measure Information 2026 Performance Period 2027 Performance Period
Title Screening for Abnormal Glucose Metabolism in Patients at Risk of Developing Diabetes Screening for Abnormal Glucose Metabolism in Patients at Risk of Developing Diabetes
CMS eCQM ID CMS1154v1 CMS1154v2
CBE ID* Not Applicable Not Applicable
MIPS Quality ID 515 515
Measure Steward American Medical Association (AMA) American Medical Association (AMA)
Description

Percentage of adult patients with risk factors for type 2 diabetes who are due for glycemic screening for whom the screening process was completed during the measurement period.

Percentage of adult patients with risk factors for type 2 diabetes who are due for glycemic screening for whom the screening process was completed during the measurement period

Measure Scoring Proportion Proportion
Measure Type Process Process
Stratification

None

None

Risk Adjustment

None

None

Rationale

This measure is critical to identifying patients with prediabetes who may benefit from interventions to prevent type 2 diabetes and identification of undiagnosed type 2 diabetes. The Centers for Disease Control and Prevention (CDC) estimates that approximately 97.6 million American adults have prediabetes (CDC, 2024). They note that more than 80% of adults with prediabetes are not aware that they have the condition. Regular screening for prediabetes is a critical first step to helping patients avoid the disability and costs associated with progression to type 2 diabetes.

The measure gives credit for three types of tests that can be used to detect abnormal glucose metabolism: HbA1c, oral glucose tolerance, and fasting plasma glucose. When considering which plasma glucose screening codes to include in the measure, the measure development team carefully considered two potential unintended consequences related to the limited use of accompanying fasting status codes. If the measure specified plasma glucose screening too narrowly, it could incentivize over screening, which would impose added burden on clinicians and increased costs to some patients. Alternatively, if the measure specified plasma glucose screening too broadly, it could give credit for non-fasting plasma glucose tests that are not adequate for diagnostic purposes.

This measure is critical to identifying patients with prediabetes who may benefit from interventions to prevent type 2 diabetes and identification of undiagnosed type 2 diabetes. The Centers for Disease Control and Prevention (CDC) estimates that approximately 97.6 million American adults have prediabetes (CDC, 2024). They note that more than 80% of adults with prediabetes are not aware that they have the condition. Regular screening for prediabetes is a critical first step to helping patients avoid the disability and costs associated with progression to type 2 diabetes.

The measure gives credit for three types of tests that can be used to detect abnormal glucose metabolism: HbA1c, oral glucose tolerance, and fasting plasma glucose. When considering which plasma glucose screening codes to include in the measure, the measure development team carefully considered two potential unintended consequences related to the limited use of accompanying fasting status codes. If the measure specified plasma glucose screening too narrowly, it could incentivize over screening, which would impose added burden on clinicians and increased costs to some patients. Alternatively, if the measure specified plasma glucose screening too broadly, it could give credit for non-fasting plasma glucose tests that are not adequate for diagnostic purposes.

Clinical Recommendation Statement

The U.S. Preventive Services Task Force (USPSTF) recommends screening for prediabetes and type 2 diabetes in adults aged 35 to 70 years who have overweight or obesity. Clinicians should offer or refer patients with prediabetes to effective preventive interventions (B recommendation) (USPSTF, 2021).

Evidence on the optimal screening interval for adults with an initial normal glucose test result is limited. Cohort and modeling studies suggest that screening every 3 years may be a reasonable approach for adults with normal blood glucose levels (USPSTF, 2021).

Prediabetes and type 2 diabetes can be detected by measuring fasting plasma glucose or HbA1c level, or with an oral glucose tolerance test. A fasting plasma glucose level of 126 mg/dL (6.99 mmol/L) or greater, an HbA1c level of 6.5% or greater, or a 2-hour post-load glucose level of 200 mg/dL (11.1 mmol/L) or greater are consistent with the diagnosis of type 2 diabetes. A fasting plasma glucose level of 100 to 125 mg/dL (5.55-6.94 mmol/L), an HbA1c level of 5.7% to 6.4%, or a 2-hour post-load glucose level of 140 to 199 mg/dL (7.77-11.04 mmol/L) are consistent with prediabetes (USPSTF, 2021).

The U.S. Preventive Services Task Force (USPSTF) recommends screening for prediabetes and type 2 diabetes in adults aged 35 to 70 years who have overweight or obesity. Clinicians should offer or refer patients with prediabetes to effective preventive interventions (B recommendation) (USPSTF, 2021).

Evidence on the optimal screening interval for adults with an initial normal glucose test result is limited. Cohort and modeling studies suggest that screening every 3 years may be a reasonable approach for adults with normal blood glucose levels (USPSTF, 2021).

Prediabetes and type 2 diabetes can be detected by measuring fasting plasma glucose or HbA1c level, or with an oral glucose tolerance test. A fasting plasma glucose level of 126 mg/dL (6.99 mmol/L) or greater, an HbA1c level of 6.5% or greater, or a 2-hour post-load glucose level of 200 mg/dL (11.1 mmol/L) or greater are consistent with the diagnosis of type 2 diabetes. A fasting plasma glucose level of 100 to 125 mg/dL (5.55-6.94 mmol/L), an HbA1c level of 5.7% to 6.4%, or a 2-hour post-load glucose level of 140 to 199 mg/dL (7.77-11.04 mmol/L) are consistent with prediabetes (USPSTF, 2021).

Improvement Notation

Increased score indicates improvement - Higher score equals better quality

Higher score equals better quality

 

Definition

None

None

Guidance

The measure is limited to patients aged 35 to 70 with overweight or obesity because it is recommended that all patients with those risk factors be screened for diabetes at least once every three years. However, this measure is not intended to discourage screening at younger ages, which the USPSTF recommends considering for adults with overweight or obesity and any of the following risk factors:

- Race/ethnicity with disproportionately high incidence and prevalence of diabetes (American Indian/Alaska Native, Asian American, Black, Hispanic/Latino, or Native Hawaiian/Pacific Islander persons)

- Family history of diabetes

- History of gestational diabetes

- History of polycystic ovarian syndrome

It is recommended that every patient evaluated by this measure also identify payer, race, ethnicity, and sex.

This eCQM is a patient-based measure.

This version of the eCQM uses QDM version 5.6. Please refer to the QDM page for more information on the QDM.

The measure is limited to patients aged 35 to 70 with overweight or obesity because it is recommended that all patients with those risk factors be screened for diabetes at least once every three years. However, this measure is not intended to discourage screening at younger ages, which the USPSTF recommends considering for adults with overweight or obesity and any of the following risk factors:

  • Race/ethnicity with disproportionately high incidence and prevalence of diabetes (American Indian/Alaska Native, Asian American, Black, Hispanic/Latino, or Native Hawaiian/Pacific Islander persons)
  • Family history of diabetes
  • History of gestational diabetes
  • History of polycystic ovarian syndrome

It is recommended that every patient evaluated by this measure also identify payer, race, ethnicity, and sex.

This eCQM is a patient-based measure.

This version of the eCQM uses QDM version 5.6. Please refer to the QDM page for more information on the QDM.

Initial Population

All patients with at least two outpatient clinical encounters or one preventive clinical encounter during the measurement period who have the following risk factors for type 2 diabetes:

- Most recent BMI ≥25 kg/m2 (BMI ≥23 kg/m2 for Asian patients) during measurement period, AND

- Age 35-70 at start of measurement period.

All patients with at least two outpatient clinical encounters or one preventive clinical encounter during the measurement period who have the following risk factors for type 2 diabetes:

  • Most recent Body Mass Index (BMI) ≥25 kg/m2 (BMI ≥23 kg/m2 for Asian patients) during measurement period, AND
  • Age 35-70 at start of measurement period.
Denominator

All patients in the initial population.

All patients in the initial population

Denominator Exclusions

- Patient's pregnancy overlaps measurement period.

- Patient with diagnosis of advanced illness or limited life expectancy overlaps measurement period.

- Patient with diagnosis of diabetes overlaps 2-year look-back period.

- Patient with diagnosis of prediabetes overlaps 2-year look-back period.

- Patient with glycemic screening performed during 2-year look-back period.

 

  • Patient's pregnancy overlaps measurement period.
  • Patient with diagnosis of advanced illness or limited life expectancy overlaps measurement period.
  • Patient with diagnosis of diabetes overlaps 2-year look-back period.
  • Patient with diagnosis of prediabetes overlaps 2-year look-back period.
  • Patient with glycemic screening performed during 2-year look-back period.

 

Numerator

Patients who had a glycemic screening test performed during the measurement period.

Patients who had a glycemic screening test performed during the measurement period

Numerator Exclusions

None

None

Denominator Exceptions

None

None

Telehealth Eligible Yes Yes
Reporting Options MIPS Not yet available
MVP ID Not yet available Not yet available
Next Version No Version Available
Previous Version No Version Available
Specifications and Data Elements
Release Notes

Header

TRN

Measure Section

Source of Change

Updated the eCQM version number.

eCQM Version Number

Annual Update

Updated the eCQM version number to reflect minor version addendum.

eCQM Version Number

Annual Update Addendum

Updated the measurement period from 'January 1, 2026 through December 31, 2026' to 'January 1, 2027 through December 31, 2027.'

Measurement Period

Annual Update

Updated copyright.

Copyright

Annual Update

Updated grammar, wording, and/or formatting to improve readability and consistency.

Multiple Sections

Annual Update

Updated disclaimer.

Disclaimer

Annual Update

Revised Risk Adjustment field to read 'None' to align with eCQM standard practice.

Risk Adjustment

Standards/Technical Update

Revised Improvement Notation field from 'Increased score indicates improvement' to 'Higher score equals better quality' to align with eCQM standard practice.

Improvement Notation

Standards/Technical Update

Updated all References from APA6 style to APA7 style.

Reference

Standards/Technical Update

Logic

TRN

Measure Section

Source of Change

Updated Measure Primary CQL Library Name from 'CMS1154ScreeningPrediabetesQDM' to 'CMS1154AbnlGlucMetabScreen' for alignment with the CQL Style Guide.

Definitions

Standards/Technical Update

Updated CQL definitions, functions, and/or aliases for clarification and to align with the CQL Style Guide.

Definitions

Standards/Technical Update

Updated all logic definitions to be written in initial case for alignment with the CQL Style Guide.

Definitions

Standards/Technical Update

Updated the 'Advanced Illness or Limited Life Expectancy' definition to use 'overlaps day of' to  correct a timing operator error.

Definitions

Annual Update Addendum

Updated Measure Primary CQL Library Name from 'CMS1154ScreeningPrediabetesQDM' to 'CMS1154AbnlGlucMetabScreen' for alignment with the CQL Style Guide.

Functions

Standards/Technical Update

Value Set

The VSAC is the source of truth for the value set content, please visit the VSAC for downloads of current value sets.

TRN

Measure Section

Source of Change

Value Set 'Advanced Illness' (2.16.840.1.113883.3.464.1003.110.12.1082): Added 8 ICD10CM codes (G35.A, G35.B0, G35.B1, G35.B2, G35.C0, G35.C1, G35.C2, G35.D) based on SME/Expert recommendations. Added 20 SNOMEDCT codes (702429008, 1260328002, 1343507003, 1343682000, 1344640009, 1348304006, 1359858006, 1363184005, 1363185006, 135811000119107, 235601000112100, 941871000124103, 16067571000119106, 16067651000119101, 140633841000119106, 386085001000119102, 417437921000119101, 543826841000119109, 711570201000119105, 932947661000119102) based on SME/Expert recommendations. Deleted 33 SNOMEDCT codes (1236965009, 1237491009, 1240357005, 1254729000, 1254730005, 1254731009, 1263997005, 1263998000, 1264257008, 1264496004, 1264498003, 1264521002, 1264523004, 1264524005, 1268355005, 233765002, 705176003, 733185001, 781076008, 94176003, 94177007, 94182000, 94244003, 94276008, 94277004, 94297009, 94385006, 94387003, 94401004, 94443006, 94444000, 94653000, 94655007) based on SME/Expert recommendations.

Terminology

Annual Update

Value Set 'Diabetes' (2.16.840.1.113883.3.464.1003.103.12.1001): Code(s) Added 6 SNOMEDCT codes (1344623000,1354552000, 1354553005, 1354554004, 267604001, 58581000087105) based on SME/Expert recommendations. Deleted 3 SNOMEDCT codes (703136005, 703137001, 703138006) based on SME/Expert recommendations. Deleted 1 ICD10CM codes (E10.A2) based on SME/Expert recommendations.

Terminology

Annual Update

Value Set 'Payer Type' (2.16.840.1.114222.4.11.3591): Deleted 42 SOPT codes (111, 1112, 3111, 3112, 3114, 3115, 3116, 3119, 3121, 3122, 3211, 3212, 32121, 32122, 32123, 32124, 32125, 32126, 32127, 32128, 3222, 3223, 3229, 3711, 3712, 3713, 3811, 3812, 3813, 3819, 6, 61, 611, 612, 613, 614, 619, 62, 621, 622, 623, 629) based on new or changed coding guidance.

Terminology

Annual Update

Last Updated: Sep 29, 2026